ReviewHuman vaccines & immunotherapeutics2016
Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.Human vaccines & immunotherapeutics · 2022Pooled it
- Pooled it
- Pooled it
- Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial.Human vaccines & immunotherapeutics · 2023Trial
- Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.Human vaccines & immunotherapeutics · 2022Trial
- Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age.Human vaccines & immunotherapeutics · 2021Trial
- A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States.Human vaccines & immunotherapeutics · 2021Trial
- Epidemiological approaches to evaluate clinical unmasking of HPV-associated cervical lesions in the HPV vaccination era.International journal of cancer · 2026Review
- HPV Type Replacement After HPV Vaccination.Current topics in microbiology and immunology · 2026Review
- Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure.Human vaccines & immunotherapeutics · 2025Review
- Review
- Safety and efficacy of an intramuscular bivalent vaccine against influenza and Streptococcus pneumoniae infections in mice.Medical microbiology and immunology · 2025Article
- Population structure, antibiotic resistance and molecular characteristics ofJournal of medical microbiology · 2025Article
- Predominant Pneumococcal Serotypes in Isolates Causing Invasive Disease in a Spanish Region: An Examination of Their Association with Clinical Factors, Antimicrobial Resistance, and Vaccination Coverage.Journal of clinical medicine · 2025Article
- Chemical Synthesis of Truncated Capsular Oligosaccharide of Serotypes 6C and 6D ofACS infectious diseases · 2024Article
- Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.Infectious diseases and therapy · 2024Article
- Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016-2020: The CAPA Study.Microorganisms · 2023Article
- PfaSTer: a machine learning-powered serotype caller forMicrobial genomics · 2023Article
Corrections and comments
- Erratum issuedCorrigendum.2016
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Streptococcus pneumoniae has more than 95 serotypes, each of which presumably can cause sepsis, meningitis, pneumonia, and acute otitis media. Pneumococcal conjugate vaccines (PCV) targeted against a limited number of serotypes have nonetheless revealed an impressive impact on each manifestation of pneumococcal disease. At the same time, growing evidence of significant non-vaccine type (NVT) replacement disease following implementation of infant PCV programs has raised questions about the long-term viability of PCV immunization strategies and how to optimize PCV formulations. We discuss here theoretical and practical considerations regarding serotype replacement, and provide a snapshot of the most important NVT types seen to date after implementation of the 2 higher-valent PCVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.